Changeable proteins cause nerve disease

An incorrectly folded protein is one of the reasons behind the nerve disease ALS, according to new research. But the protein does not have structural errors all the time and only certain types contribute to the harmful protein accumulations that cause the ALS disease.

BMAs: Run your own business

After graduation you must decide: be an employee or start your own business. This is not really the situation for BMAs today, but a collaborative project between Swedish public actors and some companies aims to change that and make entrepreneurs of BMAs.

Hey Klementina Österberg ...

... CEO at GU Holding, which awards SEK 120, 000 to three female entrepreneurs.

Mingling do's and don'ts

Linkedin, Facebook, MSN and Gmail are all perfect tools for the urban businessman or woman to keep track of and stay up-to-date with contacts. "But in the end, networking is about meeting and talking to people face-to-face," says mingling expert Mia Forsgren at Begriplig.

Diagnostics for personalized medicine

Per Matsson from Phadia anticipates changes in the standards for health care. Accordiing to him, expensive new drugs will create a market for more extensive diagnostics.

A crash course in IP strategy

"Publish, publish, publish!" Sound familiar? So to meet the researcher's wishes, do you scribble a patent application with lipstick on a napkin and send it in? At the seminar Patent Strategies in the Biotech Company, you will have the chance to find out

Två steg framåt för Bioinvent

Bioinvent och partnern Trombogneics har avslutat fas I studien av cancersubstansen TB-403. Resultaten visar att substansen tolereras väl och endast ger ett fåtal biverkningar. Nyligen slöt också det svenska bolaget ett licensavtal med japanska Daiichi.

Cate Poulsen, Qiagen

Why are you going to Scanlab and Biotech Forum?

How to get the most out of the fair

From planning stage to handshake

"Partnering is an effective tool to get in touch with the decision makers high up in an organization's administration," says Camilla Huse Bondeson at Conlega. And according to her, rigorous planning is the way to succeed.

Uppfinningsrikt företag prisat

Diagenic har utsetts till årets mest innovativa företag av det norska forskningsrådet. Priset är till för att uppmuntra ökad FoU-verksamhet.

Steven Burrill vill starta svensk fond

Investeraren och analytikern Steven Burrill var nyligen i Sverige för besluta om han ska starta en svensk eller nordisk life science-fond. - Det finns mycket större tillväxtmöjligheter här än vad många tror, säger Steven Burrill.

The winner of the race

She learned how to work hard at an early age and her devotion has certainly paid off. Whether it is field running or running a company, the key to success is focus according to Yvonne Mårtensson.

Ny serie av svepelektronmikroskop från FEI

Den nya 50-serien av Quanta från FEI Company är familj svepelektronmikroskop som kan visa bilder av mjuka, icke-ledande prover och dynamiska processer.

Danskt forskningsföretag topprankas

Bäst i Europa på forskning och utveckling, anser Frost & Sullivan.

Sophion etablerar sig i Japan

Öppnar nytt sälj och supportkontor som ska ledas av en ledande japansk elektrofysiolog.

Major changes to the Q-Med board

The nomination committee wants to replace half of the existing board, including the current Chairman. An Extraordinary General Meeting will take place on February 4.

Swedish top scientists to EMBO

Two Swedish top scientists will have a really good chance to influence European life science research from now on. One is from the Karolinska Institutet, and one is from the University of Uppsala.

Faster sales but less profits for Probi

The probiotic company increases its turnover, and the net results are twice as large as last year.

Symphogen buys tumor blocking technology

The seller is a pioneer in developing ligand traps to treat cancer and other diseases. "An excellent fit with our scientific and strategic focus," said Kirsten Drejer, CEO of Symphogen. Ph.D.

Teams up with leading dermatologist

Tripep has signed a letter of intent with a major Japanese specialty pharma company to bring their wound healing treatment to a big market.

Athera signs production partnership

The companys novel cardiovascular product will be manufactured in Germany.

Go ahead for leg wound study

Tripep starts a phase II-study of their wound healing joint venture project.

First ever study of human stem cell treatment

The FDA says yes to the world's first study in man of a human embryonic stem cell based therapy to treat spinal injury.